Bristol CEO Lamberto Andreotti will step down as CEO in May but remain as chairman of the board, making way for insider Giovanni Caforio to take over the top slot. His task will be overseeing Bristol’s transition to a commercial-stage immuno-oncology powerhouse.
Bristol-Myers Squibb Co. has appointed Chief Operating Officer Giovanni Caforio to be the company’s next chief executive in its bid to become the industry’s leading immuno-oncology player. He will succeed CEO Lamberto Andreotti effective May 5 in what appears to be a well-planned succession strategy.
Andreotti, who has served as CEO since May 2010, will take over as chairman of the board, replacing his predecessor...
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
